Drug Target Review

NOVEMBER 8, 2023

Problem w/ CTs and foundational understanding of Vittoria: can you explore the current limitations of cell therapies and the challenges faced by patients and providers? Currently, only a small percentage of cancers can be effectively treated with cell therapies, and there is little diversity in the currently approved products.

Therapies 116

Therapies Engineering Treatment Molecular Biology 116

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Drug Target Review

JANUARY 15, 2024

Research 1 has shown that neutrophil elastase selectively and potently kills cancer cells irrespective of their genetics and anatomical origin, mobilises adaptive immunity, and avoids resistance mechanisms. Could you provide insights into the driving factors behind exploring novel treatments for cancer types?

Treatment 105

Treatment Immune Response Therapies Clinical Trials 105

Drug Target Review

NOVEMBER 17, 2023

They do not induce ‘graft versus host’ disease when transplanted for allogeneic therapy and there appears little sign of immune rejection. Peripheral blood NK cells have been used in allogeneic cancer therapies and shown to be safe. Only three of the CAR-NK studies were for the treatment of solid tumours.

Therapies 118

Therapies Cell Biology Clinical Trials Trials 118

PPD

OCTOBER 17, 2024

Cell and gene therapy (CGT) studies are rapidly gaining momentum in the Asia-Pacific region, fueled by growing patient demand and a thriving ecosystem of innovation. In China, the high incidence of solid tumors is driving an urgent need for advanced therapies, spurring the push for new treatment approaches.

Therapies 97

Therapies Clinical Trials Clinical Research Trials 97

Drug Target Review

MARCH 7, 2024

Researchers from the University of California, San Francisco have designed a candidate drug that modifies the cancer-causing mutation K-Ras G12D, which could turn pancreatic cancer into a treatable condition. Since then, two therapies have been approved for use in lung and breast cancer but it did not advance pancreatic cancer treatment.

Treatment 98

Treatment Therapies Clinical Trials Research 98

Broad Institute

OCTOBER 11, 2023

Manguso, who’d recently graduated from college and was conducting research at the University of Copenhagen as a Fulbright scholar, moved back to the Boston area to be with his mother as she underwent treatment. It was already becoming clear that some cancers responded better than others to immunotherapy.

Research 137

Research Immune Response Clinical Trials Therapies 137

Broad Institute

NOVEMBER 21, 2024

Researchers identify source of a brain cancer’s deadly transformation By Corie Lok November 21, 2024 Breadcrumb Home Researchers identify source of a brain cancer’s deadly transformation Slow-growing glioma tumors become more aggressive when their cells shift identities and acquire new genetic mutations.

Research 124

Research Medical Schools DNA Hospitals 124

Drug Target Review

AUGUST 22, 2023

This Q&A explores how pre-clinical research is being used to identify potential therapies for Huntington’s disease, a devastating condition that currently lacks disease- modifying treatments. What makes the potential therapeutic for Huntington’s disease unique compared to other treatments?

Therapies 98

Therapies Disease RNA Treatment 98

Drug Target Review

JUNE 27, 2023

This ebook delves into the intricate world of cancer therapies, immune system breakthroughs, therapeutic genetic engineering, and groundbreaking advancements in gene editing, featuring insightful interviews with renowned experts in the field.

Therapies 105

Therapies Immune Response Engineering Drugs 105

Science Daily: Pharmacology News

MARCH 7, 2024

Four children have remained free of detectable HIV for more than one year after their antiretroviral therapy (ART) was paused to see if they could achieve HIV remission, according to new research.

Treatment 129

Treatment Clinical Trials Therapies Trials 129

Drug Target Review

OCTOBER 11, 2023

Most of these conditions are genetic in origin and the majority have no effective treatment. 1,2 Many, however, do have dysfunctional proteins at their core, and for these diseases, a new option is being explored: autophagy-boosting therapies. Gene therapy, of course, also holds great promise.

Disease 113

Disease Treatment Small Molecule Therapies 113

Science Daily: Pharmacology News

OCTOBER 18, 2023

Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months.

Therapies 88

Therapies Immune Response Research Virus 88

Drug Target Review

JANUARY 4, 2024

What distinguishes Alder Therapeutics’ approach to regenerative cell therapy development from traditional methods, and how does it aim to reduce risks in the preclinical phase? Traditional approaches to regenerative cell therapy development are defined by several challenges. So, what makes these therapies unique?

Therapies 98

Therapies Small Molecule Production Disease 98

Fierce BioTech

NOVEMBER 21, 2023

Cell and Gene Therapy (CGT) has the potential to transform the life trajectory of children with genetic conditions amendable to gene modification with advances in treatment and possible cures. Pediatric CGT trials have the potential to cure diseases and prolong lives.

Therapies 91

Therapies Research Trials Treatment 91

Drug Target Review

AUGUST 31, 2023

Stem cell therapies have already demonstrated their prowess in treating diverse cancers and ailments linked to the blood and immune system. Upon further examination of the brain tissue, the researchers observed a significant reduction in β-amyloid plaques in the hippocampus and cortex of mice treated with healthy stem cells.

Therapies 105

Therapies Disease Research Treatment 105

Broad Institute

SEPTEMBER 6, 2023

Diabetes and cardiac fibrosis are two conditions in dire need of new therapies,” said Todd Golub, director of the Broad Institute. For both patient populations, there are no safe and effective therapies for reversing disease. Florez is an institute member at the Broad, where he directs the Diabetes Research Group.

Disease 136

Disease Research Therapies Treatment 136

Antidote

JUNE 7, 2023

Before any new medical treatment, therapy, or device is approved, it must first be tested through clinical research studies. While some research studies seek participants with illnesses or conditions to be studied in the clinical trial, it is not always necessary to have a specific illness or condition to participate.

Research 98

Research Clinical Trials Clinical Research Trials 98

Drug Target Review

OCTOBER 5, 2023

This innovative approach involves the extraction of a patient’s own stem cells from either their bone marrow or blood , followed by a course of chemotherapy and antibody treatment. The research team identified 231 individuals diagnosed with relapsing-remitting MS, with 174 of them having undergone aHSCT treatment before the year 2020.

Therapies 116

Therapies Treatment Clinical Trials Disease 116

Drugs.com

JUNE 10, 2024

MONDAY, June 10, 2024 — Though overdose deaths continue to surge, there is no approved medication to treat methamphetamine use disorder.Now, an experimental two-drug therapy has yielded promising results, UCLA researchers report."These These findings h.

Treatment 111

Treatment Drugs Therapies Research 111

Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years.

Therapies 114

Therapies Disease Engineering Medical Schools 114

Drug Target Review

OCTOBER 2, 2024

Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. However, cell-based therapies are intended to leverage those healthy cells via transplant to regenerate damaged tissue.

Therapies 98

Therapies Disease Engineering RNA 98

PLOS: DNA Science

MARCH 28, 2024

FDA classifies it as a “nonsteroidal treatment” – not a gene therapy, but it affects gene expression. Research also took place in two facilities in Italy, with sponsorship from Italfarmaco S.p.A. A gene-based treatment would have to alter many cells to exert a noticeable effect. million DNA bases.

FDA Approval 98

FDA Approval Treatment FDA DNA 98

BioPharma Drive: Drug Pricing

JULY 12, 2023

The decision to explore “strategic alternatives” comes about six weeks after the company sold its most advanced treatment to Novartis for nearly $90 million.

Therapies 98

Therapies Research Treatment 98

Drug Target Review

JULY 31, 2023

Our inaugural report is a groundbreaking exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery. Expert Insights We are honoured to have collaborated with renowned experts in the field of cell and gene therapy, who have generously shared their invaluable insights.

Therapies 98

Therapies Disease Clinical Development Hospitals 98

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies 105

Therapies Engineering Molecular Biology Science 105

Drug Target Review

DECEMBER 12, 2023

This has several advantages, including increased speed of development, cost-effectiveness and leveraging already established and extensively researched antibodies. Can you provide more details on ARC-02, Araris’ lead candidate, and what it is designed to treat? non-dilutive financing from the Swiss Accelerator Grant (5% funding rate).

Treatment 114

Treatment Engineering Pharmacokinetics Doctors 114

Drug Target Review

NOVEMBER 29, 2023

Our primary focus is to design and develop RNA therapies for liver diseases. Our team of chemists then uses this information to develop novel therapies. By doing this, we get a superior understanding of which therapies will and will not work in human biology before a clinical trial. As a result, waiting lists continue to grow.

Therapies 102

Therapies Disease RNA Engineering 102

SCIENMAG: Medicine & Health

MARCH 4, 2024

Researchers who work with tiny drug carriers known as lipid nanoparticles have developed a new type of material capable of reaching the lungs and the eyes, an important step toward genetic therapy for hereditary conditions like cystic fibrosis and inherited vision loss. Researchers who work […] PORTLAND, Ore.

Research 74

Research Treatment Disease Therapies 74

Drug Target Review

SEPTEMBER 22, 2023

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. The derived drug was given to both patients, to which researchers report the patients saw significant improvement. Elsevier; 2020.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

Drug Target Review

FEBRUARY 1, 2024

What challenges has the industry faced in developing and commercialising treatments for neurological diseases, including rare diseases? Historically, what has limited investor interest in funding neurological and psychiatric therapies in development? All stakeholders have benefited from these innovations.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drugs.com

DECEMBER 13, 2024

13, 2024 -- The ancient Japanese practice of reiki "energy healing" might help some cancer patients deal with the pain that can come with infusion therapies, new research shows. FRIDAY, Dec. Outpatients receiving reiki during infusion reported.

Treatment 90

Treatment Therapies Research 90

Drug Target Review

SEPTEMBER 1, 2023

Could you explain the fundamental distinction between autologous and allogeneic cell therapies and how they differ in terms of cell sourcing and application? Autologous immune cell therapy involves the grafting of a patient’s own immune cells. Then, cells are infused back to that same patient.” There are pros and cons to each.

Therapies 105

Therapies Engineering Production Clinical Trials 105

Drug Target Review

DECEMBER 13, 2024

2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates. 7 Recent clinical studies highlight promising developments in c-MET-targeting ADCs for NSCLC.

Therapies 52

Therapies Treatment Clinical Trials Drugs 52

Drugs.com

JANUARY 22, 2024

Now, research shows that two leading modes of treatment -- antidepressants and an approach called behavioral activation. MONDAY, Jan. 22, 2024 -- Depression affects half of the 6 million Americans who struggle with debilitating heart failure.

Therapies 116

Therapies Treatment Research 116

Drug Target Review

JUNE 8, 2023

In this article, Dr Andy Souers, distinguished research fellow at AbbVie in Oncology Discovery Research, discusses a 20-year quest for AbbVie researchers to find an enhanced therapeutic chemotherapy-free approach for blood cancer, that restores the body’s ability to fight cancer.

Treatment 105

Treatment Organic Chemistry Research Disease 105

Chemical Biology and Drug Design

MAY 2, 2024

Simultaneous inhibition of EGFR and VEGFR2 may improve the efficacy of cancer treatment. Abstract Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor 2 (VEGFR2) are known as valid targets for cancer therapy.

Therapies 100

Therapies Treatment Drugs Research 100